全球宮頸癌治療市場-2022-2029

市場動態

宮頸癌患病率上升、政府積極舉措、公眾意識提高、靶向治療的新進展以及強大的藥物管道正在推動市場發展。

越來越多的 FDA 批准宮頸癌治療藥物有望推動市場增長。

2021 年 9 月 20 日，美國食品和藥物管理局批准了 tisotumab vedotin-tftv (Tivdak, Seagen Inc.)，一種組織因子導向抗體和微管抑製劑的偶聯物，用於治療化療期間或之後的疾病。加速批准患有晚期復發性或轉移性宮頸癌的成年患者。 2021 年 10 月 13 日，默克公司宣布美國食品藥品監督管理局 (FDA) 已批准在 FDA-批准的測試。宣布默克公司的抗 PD-1 療法 KEYTRUDA 與化療聯合或不聯合貝伐單抗治療患者的批准。該批准是基於 KEYTRUDA 和化療（紫杉醇加順鉑或紫杉醇加卡鉑）與使用或不使用貝伐單抗的相同化療方案進行比較的 3 期 KEYNOTE-826 試驗。此外，在聯合國非傳染性疾病工作組的領導下，七個聯合國機構將啟動一項宮頸癌預防和控制聯合計劃，提供全球領導力和技術援助，為政府和合作夥伴制定計劃，並支持可持續活動.因此，從上述陳述來看，預計市場將在預測期內受到驅動。

限制

治療成本飆升、與癌症治療相關的副作用、在降低成本的同時改善臨床特徵的靶向藥物稀缺，以及新興國家對癌症治療缺乏認識，這些都是在預測期內影響市場的因素。可能是一種威懾。

行業分析

宮頸癌治療市場根據各種行業因素（包括未滿足的需求、定價分析、供應鏈分析和監管分析）對市場進行了深入分析。

全球宮頸癌治療市場報告提供大約 45 多個市場數據表、40 多個數字和 180 頁內容。

內容

第一章研究方法與範圍

• 調查方法
• 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第 4 章市場動態

• 市場影響因素
  • 驅動程序
    • 由於 FDA 對宮頸癌藥物的批准增加，預計市場將增長。
  • 限制因素
    • 預計與癌症治療相關的飆升的治療成本和副作用將阻礙市場增長。
  • 機會
  • 影響分析

第五章行業分析

• 波特的五種力量
• 未滿足的需求
• 供應鏈
• 定價分析
• 監管分析

第 6 章 COVID-19 分析

• COVID-19 的市場分析
  • COVID-19 之前的市場情景
  • COVID-19 的當前市場情景
  • COVID-19 後或未來情景
• COVID-19 期間的價格動態
• 供需範圍
• 大流行期間與市場相關的政府舉措
• 製造商的戰略舉措
• 總結

第 7 章按類型

• 鱗狀細胞癌
• 腺癌
• 腺鱗癌

第 8 章治療

• 放射治療
• 化療
• 靶向治療
• 免疫療法
• 聯合療法

第 9 章，最終用戶

• 醫院
• 癌症醫院
• 診斷中心
• 其他

第 10 章按地區劃分

• 北美
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲
  • 德國
  • 英國
  • 法國
  • 意大利
  • 西班牙
  • 其他歐洲
• 南美洲
  • 巴西
  • 阿根廷
  • 其他南美洲
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳大利亞
  • 其他亞太地區
• 中東和非洲

第 11 章競爭格局

• 競爭場景
• 市場情況/份額分析
• 併購分析

第 12 章公司簡介

• F. Hoffmann-LA Roche AG
  • 公司概況
  • 產品組合和描述
  • 主要亮點
  • 財務摘要
• Merck & Co., Inc.
• GlaxoSmithKline PLC
• Allergan PLC
• Pfizer, Inc
• Biocon Ltd
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• CooperSurgical, Inc.
• Ethicon, Inc.
• Eli Lilly & Co.
• Teva Pharmaceutical Industries Ltd.
• Varian Medical Systems, Inc.

Market Overview

Cervical Cancer Treatment Market size is projected to reach USD billion by 2029, with growth at a CAGR of 5% during the forecasting period (2022-2029).

The cervix is the lower part of the uterus that connects to the vagina. Cervical cancer begins in the cells of the cervix. Most cervical malignancies are caused by strains of the sexually transmitted pathogen, Human Papillomavirus (HPV). When healthy cells mutate, the illness begins, resulting in uncontrolled cell growth. These cells form a tumor, which spreads to the surrounding tissues. Cervical cancers are divided into squamous cell carcinomas, adenocarcinomas, and adenosquamous carcinomas. Adenocarcinomas develop from gland cells, whereas squamous cell carcinomas develop from ectocervical cells. Cancer cells are supposed to mimic squamous cells under the microscope. In adenosquamous carcinomas, squamous cell carcinomas and adenocarcinomas coexist.

Cryosurgery, laser surgery, simple hysterectomy, radical hysterectomy, and trachelectomy are all treatments for cervical cancer. Cystoscopy, proctoscopy, anesthesia, and imaging tests such as computed tomography (CT), magnetic resonance imaging (MRI), intravenous urography, and Positron Emission Tomography are used to identify cervical cancer (PET scan).

Market Dynamics

The market is driven by increased prevalence of cervical cancer, proactive government initiatives, awareness among people, new advancements in targeted therapies, and a strong pipeline of drugs.

Increasing FDA approvals for cervical cancer drugs is expected to drive market growth.

On September 20, 2021, the Food and Drug Administration granted accelerated approval to tisotumab vedotin-tftv (Tivdak, Seagen Inc.), a tissue factor-directed antibody and microtubule inhibitor conjugate, for adult patients with recurrent or metastatic cervical cancer who have disease progression during or after chemotherapy. On October 13, 2021, Merck announced that the U.S. Food and Drug Administration (FDA) had approved KEYTRUDA, Merck's anti-PD-1 therapy, in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent or metastatic cervical cancer whose tumors express PD-L1 (Combined Positive Score [CPS] ≥1)as determined by an FDA-approved test. The approval is based on Phase 3 KEYNOTE-826 trial evaluating KEYTRUDA plus chemotherapy (paclitaxel plus cisplatin or paclitaxel plus carboplatin) to the same chemotherapy regimens, with or without bevacizumab. Moreover, Seven UN agencies under the United Nations Task Force on non-communicable diseases have established a Joint Programme to prevent and control cervical cancer to provide global leadership and technical assistance to support governments and partners in building and sustaining programs. Thus, from the above statements, the market is expected to drive in the forecast period.

Restraint:

High cost of treatment and adverse effects associated with cancer therapy, less number of targeted drugs with improved clinical profile at reduced costs, and lack of awareness of cancer treatment in developing countries are going to restrain the market in the forecast period.

Industry Analysis

The cervical cancer treatment market provides in-depth analysis of the market based on various industry factors such as unmet needs, pricing analysis, supply chain analysis, regulatory analysis etc.

Segment Analysis

Chemotherapy segment is expected to hold the largest market share in the cervical cancer treatment market.

Chemotherapy uses anti-cancer drugs injected into a vein or given by mouth. These drugs enter the bloodstream and can reach all body areas, making this treatment useful for killing cancer cells in most body parts. For some stages of cervical cancer, the preferred treatment is radiation and chemo, called concurrent chemoradiation. The chemo helps the radiation work better. The chemo drugs most often used to treat advanced cervical cancer includes Cisplatin, Carboplatin, Paclitaxel (Taxol), Topotecan, and Gemcitabine (Gemzar). Therefore, it has increased the demand for chemotherapy drugs. Thus, from the above statements, the market segment accounted for the largest market share in the forecast period.

Geographical Analysis

North American region is expected to hold the largest market share in the global cervical cancer treatment market.

North America was the dominant region in the global cervical cancer treatment market and is expected to continue its dominance over the forecast period. This growth is attributed to a growing number of patients, increasing market penetration of drugs, and easy accessibility to advanced treatments. According to the American Cancer Society, in 2021, an estimated 1.9 million new cancer cases will be diagnosed and 608,570 cancer deaths in the United States. In contrast, in 2022, about 14,100 new cases of invasive cervical cancer will be diagnosed, and about 4,280 women will die from cervical cancer. Therefore, it has increased the demand for cervical cancer treatment in the region.

Moreover, on September 20, 2021, Seagen Inc. and Genmab A/S granted the U.S. Food and Drug Administration (FDA) approval to TIVDAK (tisotumab vedotin-tftv), the first and only approved antibody-drug conjugate (ADC) for the treatment of adult patients with recurrent or metastatic cervical cancer who have disease progression during or after chemotherapy. TIVDAK was authorized under the FDA's Accelerated Approval Program based on tumor response and response durability. Continued approval may rely on verifying and describing clinical benefits in confirmatory trials.

Competitive Landscape

Major key players in the cervical cancer treatment market are F. Hoffmann-LA Roche AG, Merck & Co., Inc., GlaxoSmithKline PLC, Allergan PLC, Pfizer, Inc., Biocon Ltd., Bristol-Myers Squibb Company, AstraZeneca PLC, CooperSurgical, Inc., Ethicon, Inc., Eli Lilly & Co., Teva Pharmaceutical Industries Ltd. and Varian Medical Systems, Inc.

Pfizer, Inc.:

Overview:

Pfizer Inc. is an American multinational pharmaceutical company that offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. It has a portfolio of over 150 products across 15 therapeutic areas. The company develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, endocrinology, and neurology.

Product Portfolio:

ZIRABEV (bevacizumab-bvzr): Zirabev has been approved for a number of cancer types and stages, in some cases as a single therapy, and in some cases in combination with other therapies.

Zirabev is approved for:

Colorectal cancer

Non-small cell lung cancer

Glioblastoma

Kidney cancer

Cervical cancer

Ovarian cancer

The global cervical cancer treatment market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing FDA approvals for cervical cancer drugs is expected to drive market growth.
  • 4.1.2. Restraints:
    • 4.1.2.1. High cost of treatment and adverse effects associated with cancer therapy is expected to hamper the market growth.
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Forces
• 5.2. Unmet Needs
• 5.3. Supply Chain
• 5.4. Pricing Analysis
• 5.5. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 7.1.2. Market Attractiveness Index, By Type Segment
• 7.2. Squamous Cell Carcinoma*
  • 7.2.1.1. Introduction
  • 7.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 7.3. Adenocarcinoma
• 7.4. Adenosquamous Carcinoma

8. By Treatment

• 8.1. Introduction
  • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 8.1.2. Market Attractiveness Index, By Treatment Segment
• 8.2. Radiation Therapy*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 8.3. Chemotherapy
• 8.4. Targeted Therapy
• 8.5. Immunotherapy
• 8.6. Combined Therapy

9. By End user

• 9.1. Introduction
  • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  • 9.1.2. Market Attractiveness Index, By End user Segment
• 9.2. Hospitals*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 9.3. Specialized Cancer Centers
• 9.4. Diagnostic Centers
• 9.5. Others

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. U.K.
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. F. Hoffmann-LA Roche AG*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Key Highlights
  • 12.1.4. Financial Overview
• 12.2. Merck & Co., Inc.
• 12.3. GlaxoSmithKline PLC
• 12.4. Allergan PLC
• 12.5. Pfizer, Inc
• 12.6. Biocon Ltd
• 12.7. Bristol-Myers Squibb Company
• 12.8. AstraZeneca PLC
• 12.9. CooperSurgical, Inc.
• 12.10. Ethicon, Inc.
• 12.11. Eli Lilly & Co.
• 12.12. Teva Pharmaceutical Industries Ltd.
• 12.13. Varian Medical Systems, Inc.